Document Detail


A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine.
MedLine Citation:
PMID:  8364131     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ninety-two patients with duodenal ulcer disease, who had received long-term continuous treatment with ranitidine for an average of 7.5 years, participated in a double-blind, placebo-controlled study to determine whether stopping ranitidine resulted in ulcer recurrence. Patients were randomized to continue with ranitidine (n = 46) or to receive placebo (n = 46) and were followed up for six months. Treatment failure was defined as the first symptomatic recurrence of ulcer. The occurrence of epigastric pain during the follow-up period was significantly less frequent in the ranitidine group (13%) than in the placebo group (43%) (P = 0.001). At six months, 9% of the ranitidine group had developed ulcer recurrence, compared with 48% in the placebo group (P < 0.001, logrank test). Multivariate analysis using the Cox proportional hazards model showed that younger age (P = 0.041) and a long history of ulcer disease (P = 0.025) were risk factors for ulcer recurrence but gender, smoking and duration or dose of previous ranitidine treatment were not predictive of relapse during treatment with placebo. In conclusion, withdrawal of ranitidine after more than five years of continuous treatment results in almost half of the patients developing symptomatic ulcer recurrence within six months. Thus, long-term continuous therapy does not alter the natural history of duodenal ulcer disease. Younger patients and those with a long history of ulcer disease appear to be at increased risk of developing ulcer recurrence if long-term treatment is withdrawn.
Authors:
J G Penston; J S Dixon; E J Boyd; K G Wormsley
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  7     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-10-05     Completed Date:  1993-10-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  259-65     Citation Subset:  IM    
Affiliation:
Ninewells Hospital & Medical School, Dundee, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Double-Blind Method
Duodenal Ulcer / chemically induced*,  drug therapy,  epidemiology
Endoscopy, Gastrointestinal
Female
Humans
Male
Middle Aged
Multivariate Analysis
Ranitidine / adverse effects*,  therapeutic use
Recurrence
Risk Factors
Sex Factors
Smoking / adverse effects
Substance Withdrawal Syndrome*
Chemical
Reg. No./Substance:
66357-35-5/Ranitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison...
Next Document:  Zinc supplementation restores plasma concentrations of zinc and thymulin in patients with Crohn's di...